The Native Antigen Company
The Native Antigen Company is a UK-based B2B manufacturer of native and recombinant antigens, antibodies, virus-like particles, and immunoassays serving IVD developers, vaccine developers, and academic researchers across infectious and adjacent disease areas.
- Company typePrivate
- Founded2010
- HeadquartersKidlington, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What The Native Antigen Company does
The Native Antigen Company (TNAC) is a UK-based manufacturer of native and recombinant antigens, antibodies, virus-like particles (VLPs), toxins, and immunoassays used in infectious disease diagnostics, vaccine development, and academic research. Founded in 2010 and headquartered in Kidlington, Oxfordshire, the company operates an ISO9001:2015-accredited catalog of 838-900+ products spanning more than 50 viral and bacterial pathogens including Dengue, Zika, Norovirus, Cytomegalovirus, Ebola, Chikungunya, Influenza, and SARS-CoV-2. Its technical differentiator is the proprietary VirtuE™ mammalian cell expression system, which uses HEK293 (and complementary baculovirus-insect-cell and E. coli) platforms to produce native-like proteins with correct folding and glycosylation—an attribute valued by IVD kit manufacturers and vaccine developers who require biologically faithful antigens.
TNAC sells primarily through a B2B direct-to-customer model with online ordering, pricing in British Pounds per unit and quantity discounts of up to 30 percent for bulk purchases, supplemented by a network of international distributors enabling global delivery. A secondary contract services line offers custom vector design, protein expression, purification, antibody generation, immunoassay development, and endotoxin testing for biopharma and diagnostic clients on projects ranging from short-term to multi-year engagements. In October 2022 the company relocated to a 36,000 sq ft purpose-built facility at Oxford Technology Park, materially expanding manufacturing capacity and bringing its site into BREEAM sustainability certification.
The company operates as a wholly-owned subsidiary of LGC Clinical Diagnostics within the LGC Group, alongside other reagent brands such as SeraCare, Biosearch Technologies, and Maine Standards. Day-to-day leadership includes COO Nicholas Roesen; broader strategic direction sits within the parent group. No public revenue, headcount, or funding figures are disclosed in available sources.
The Native Antigen Company firmographics
Firmographics- Name
- The Native Antigen Company
- Legal name
- The Native Antigen Company
- Website
- https://thenativeantigencompany.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- The Native Antigen Company is a UK-based B2B manufacturer of native and recombinant antigens, antibodies, virus-like particles, and immunoassays serving IVD developers, vaccine developers, and academic researchers across infectious and adjacent disease areas.
- Ownership category
- akta.pro rank
The Native Antigen Company industry classification
Industry- Product category
- Infectious Disease Reagents
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industries
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where The Native Antigen Company is headquartered
LocationHeadquarters
- HQ city
- Kidlington
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
The Native Antigen Company business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Biological Reagent Products: Sale of antigens, antibodies, virus-like particles, toxins, immunoassays, and related reagents to diagnostic and biopharmaceutical companies, academic researchers, and vaccine developers. Products are sold in standard vial sizes with quantity discounts available.
- Contract Services: Custom project services including vector design, protein expression, protein purification, antibody generation, immunoassay development, and endotoxin testing. Projects range from short-term (few days) to long-term programs (year or more).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Norovirus GI.3 VLP - recombinant virus-like particles |
| Unit Pricing | Pay-as-you-go | Norovirus GI.1 VLP - recombinant virus-like particles |
| Unit Pricing | Pay-as-you-go | Mayaro Virus VLP |
| Unit Pricing | Pay-as-you-go | Dengue Virus NS1 Protein Serotypes 1-4 |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
The Native Antigen Company product offering
Product offeringCore offering
The Native Antigen Company develops and manufactures native and recombinant viral and bacterial antigens, antibodies, virus-like particles (VLPs), virus receptors, toxins, and immunoassay/NTRL kits used by in vitro diagnostic manufacturers, vaccine and biopharmaceutical developers, and academic research groups. It also offers contract production and custom assay development services, all produced under ISO9001:2015 quality standards at its 36,000 sq ft Kidlington, UK facility.
Product overview
The Native Antigen Company develops and manufactures a comprehensive portfolio of critical reagents for human health diagnostics and biopharmaceutical research. The core offerings include antigens and antibodies for over 50 viral and bacterial pathogens, virus-like particles (VLPs), virus receptors, toxins, immunoassays including SARS-CoV-2 NTRL kits, veterinary products, conjugation kits, and human disease biomarkers. The company operates a proprietary VirtuE Expression System for mammalian cell expression producing native-like proteins. Beyond products, the company offers contract services for custom antigen manufacturing, antibody generation, and assay development. Key product categories include: Antigens & Antibodies (the largest category covering pathogens like Dengue, Norovirus, Influenza, Zika), Virus-Like Particles (non-infectious recombinant viral structures), Immunoassays (including SARS-CoV-2 variant NTRL kits), and Human Disease Biomarkers (hormones and autoimmune markers). The company also provides matched pair antibodies and conjugation/labeling kits. All products are manufactured under ISO9001:2015 quality standards.
Differentiator
Problem solved
Functional benefit
Brands
- VirtuE™ Expression System: Proprietary mammalian cell expression system developed for producing native-like proteins with correct folding and glycosylation.
Products and services
- Antigens and Antibodies Native and recombinant antigens and antibodies for viral and bacterial pathogens, used by IVD manufacturers, vaccine developers, and academic researchers. Specific recombinant products have been added over time, including Rheumatoid Factor recombinant added in 2024.
- Virus-Like Particles (VLPs) Recombinant virus-like particles designed to mimic the structure of authentic viruses for use in vaccine discovery, serology assay development, and research applications.
- Virus Receptors Recombinant viral receptor proteins for use in research studying viral entry mechanisms and in assays requiring authentic receptor binding partners.
- Toxins Recombinant bacterial toxins for use in diagnostic test development, vaccine research, and academic study of bacterial pathogenesis.
- Immunoassays and NTRL Kits Immunoassay kits and Neutralisation Test Reference Lab (NTRL) kits, including SARS-CoV-2 variant kits introduced in 2022, used by diagnostic laboratories and researchers.
- Veterinary Products Infectious disease antigens and antibodies for veterinary diagnostics, animal health research, and livestock disease testing.
- Conjugation and Labeling Kits Conjugation and labeling kits enabling customers to conjugate or label antigens and antibodies for use in-house diagnostic assay development.
- Accessory Reagents Supporting accessory reagents used alongside primary antigens, antibodies, and VLPs in infectious disease immunoassays and research workflows.
- Human Disease Biomarkers Human disease biomarker reagents for use in research and diagnostic applications outside the infectious disease core catalog.
- Matched Pair Antibodies Matched antibody pairs (capture and detection antibodies) for use in sandwich immunoassays such as ELISA and lateral flow diagnostic tests.
- Contract Production and Assay Services Fee-for-service custom production of recombinant proteins, antigens, antibodies, and VLPs, plus custom assay development, delivered by PhD-level molecular biologists for IVD and vaccine customers.
Companies that use The Native Antigen Company
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
The Native Antigen Company technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
The Native Antigen Company partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- Virology Research Services (VRS)coreJoint research collaboration awarded MRC Proximity to Discovery Award for Knowledge Exchange. The partnership tested a large panel of The Native Antigen Company's viral antibodies in immunofluorescence applications, generating new immunofluorescence data for CMV, Yellow Fever, and Ebola antibodies.
- LGC Group / LGC Clinical DiagnosticsflagshipThe Native Antigen Company is part of LGC Clinical Diagnostics, a division of LGC Group. LGC is a global leader in life sciences tools and diagnostics. The new Oxford facility serves both TNAC and hosts an advanced workflow applications laboratory for LGC Biosearch Technologies.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
The Native Antigen Company competitors and assessment
Company assessmentBroad incumbents
- Merck (Millipore Sigma Life Science): Long-established life science reagents giant supplying antigens, antibodies, buffers, and assays across all research biology. Overlaps with TNAC's catalog and customer base as an incumbent; scale and catalog breadth are vastly larger, and Millipore Sigma is also a competitor for OEM reagent contracts.
- Thermo Fisher Scientific (Life Sciences Reagents): Diversified life sciences tools giant with extensive antibody, protein, and immunoassay portfolios (Invitrogen, Gibco, eBioscience). Comparable as a reagent supplier to vaccine developers and diagnostic manufacturers, but as part of a much broader portfolio across instruments, consumables, and pharma services.
- Bio-Techne (R&D Systems / Novus Biologicals): Large US-listed life science tools company spanning proteins, antibodies, ELISA kits, and reagents via R&D Systems and Novus Biologicals. Overlaps with TNAC in ELISA/kits and antibody reagents for infectious disease and immunology, but operates across all research biology, not specialising in infectious disease.
Direct peers
- Abcam (Danaher): Global leader in research-grade antibodies and reagents, now part of Danaher's Life Sciences segment. Overlaps with TNAC's antibody catalog and infectious disease focus; serves the same academic and biopharma R&D customers, though Abcam is much larger and broader.
- Sino Biological: China-based global supplier of recombinant proteins, antibodies, and assay reagents covering infectious disease, with a catalog breadth (10,000+ SKUs) far exceeding TNAC's. Compares directly as both compete head-to-head for IVD and vaccine developer reagent contracts across the same viral and bacterial pathogen menu.
- GenScript / GenScript ProBio: Recombinant protein and antibody production company with a strong biologics CDMO arm. Comparable in custom protein/antibody services and viral antigen catalog, serving overlapping IVD and vaccine developer customers.
- Biosynth (formerly Life Sciences Group / Fitzgerald Industries): Specialist chemicals, peptides, and biological reagents supplier with a meaningful infectious disease and viral antigen catalog. Comparable in target market (IVD manufacturers, vaccine researchers, academic groups) and product mix (antigens, antibodies, assay components).
- ACROBiosystems: Recombinant protein and reagent supplier focused on biopharma, with comparable strengths in viral antigens, VLPs, and viral receptor reagents. Directly comparable on target customer (vaccine/IVD developers), product format (mammalian-expressed recombinant antigens), and core differentiation (native-like structure).
- Cell Signaling Technology (CST): Specialist antibody and reagent supplier known for quality and validation rigor. Comparable on the antibody-reagent axis serving academic and translational researchers, although CST focuses more on cell signalling / oncology than infectious disease.
Emerging players
- ProSci Incorporated: Specialist custom antibody and recombinant protein supplier with infectious disease and viral antigen capabilities. Comparable to TNAC in offering custom services alongside catalog reagents, but smaller catalog breadth and more US-centric.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
The Native Antigen Company social profiles
Digital presenceThe Native Antigen Company compliance and trust
Trust signalCompliance2 records
The Native Antigen Company financial estimates
Financial estimateRevenue estimate
Valuation estimate
The Native Antigen Company leadership team
Management profileNumber of profiles
Profiles1 record
The Native Antigen Company funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The Native Antigen Company M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The Native Antigen Company
What does The Native Antigen Company do?
The Native Antigen Company develops and manufactures native and recombinant viral and bacterial antigens, antibodies, virus-like particles (VLPs), virus receptors, toxins, and immunoassay/NTRL kits used by in vitro diagnostic manufacturers, vaccine and biopharmaceutical developers, and academic research groups. It also offers contract production and custom assay development services, all produced under ISO9001:2015 quality standards at its 36,000 sq ft Kidlington, UK facility.
Is The Native Antigen Company a public or private company?
The Native Antigen Company is a private company. It is classified as corporate owned and is currently operating.
When was The Native Antigen Company founded?
The Native Antigen Company was founded in 2010. It employs 11 to 50 people.
Where is The Native Antigen Company based?
The Native Antigen Company is headquartered in Kidlington, United Kingdom, in the Europe region.
How does The Native Antigen Company make money?
Two revenue lines are on record. Biological Reagent Products are the primary driver. The others are contract Services.
Who are The Native Antigen Company's main competitors?
Broad incumbents on record are Merck (Millipore Sigma Life Science), Thermo Fisher Scientific (Life Sciences Reagents) and Bio-Techne (R&D Systems / Novus Biologicals). Direct peers are Abcam (Danaher), Sino Biological, GenScript / GenScript ProBio, Biosynth (formerly Life Sciences Group / Fitzgerald Industries), ACROBiosystems and Cell Signaling Technology (CST). ProSci Incorporated is listed as an emerging player.
Does The Native Antigen Company have an API?
No public API is recorded for The Native Antigen Company.
What industry is The Native Antigen Company in?
The Native Antigen Company's product category is Infectious Disease Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325413 and its SIC code is 2835.